Poison's board secures two seats at African Medicines technical committees
Health & Science
By
Noel Nabiswa
| Nov 07, 2026
Kenya has secured two positions on key technical committees of the African Medicines Agency (AMA), strengthening its influence in shaping medicines regulation, clinical trials oversight and access to safe medical products across the continent.
The appointments by the Pharmacy and Poisons Board (PPB) were announced during the agency’s inaugural week in Kigali, Rwanda, held under the theme, ‘Building Africa’s Regulatory Future Together: From National Strength to Continental Impact’.
While Dr Ali Abdulahi Arale, Acting Director of Medical Products and Health Technologies at PPB, has been appointed to the Technical Committee on Evaluation of Medicines, Vaccines and Biologicals, Dr Edward Abwao will serve on the Technical Committee on Clinical Trials Oversight and Good Clinical Practice, where he was also elected chairperson.
The appointments give Kenya a role in providing scientific and regulatory guidance on the assessment of medical products and the oversight of clinical research across African countries.
The committees are expected to support efforts to harmonise regulatory standards, strengthen national regulatory authorities and improve the coordination of medicines approval processes across the continent.
READ MORE
State extends high sulphur fuel import waiver by six months
Buxton contractor clarifies on project status as tensions escalate
Why more Kenyans are buying expensive smartphones on credit
Co-op Bank investors to receive Sh8.8b payout after profit surge
Irony of rising tea exports, shrinking gains for farmers
Parliament calls for special audit into Quickmart share sale
Why the super-rich are abadoning the property market
Kenya's seafarers battle unpaid wages, poor working conditions
KeNHA reports over 99 per cent axle load compliance
KEBS seeks tougher rules on imported and locally made goods as MPs review drafts
Dr Arale brings more than 25 years of professional experience, including 15 years in medicines regulation. His expertise covers the assessment of medicines and vaccines, regulatory inspections and Good Manufacturing Practice (GMP).
He has also been involved in health product registration, regulatory reliance, joint scientific reviews, capacity building and emergency use authorisation.
Dr Abwao has more than 22 years of experience in medicines regulation and has contributed to the development and establishment of Kenya’s clinical trials regulatory framework.
His areas of expertise include clinical trials oversight, post-marketing surveillance, pharmacovigilance and regulatory systems strengthening.
Established under the African Medicines Agency Treaty, AMA was created to strengthen the regulation of medical products and promote cooperation among African countries.
Its technical committees provide independent scientific advice on the evaluation of medicines, vaccines, biological products and diagnostics, as well as clinical trials oversight.
The agency's work is aimed at addressing regulatory fragmentation across African countries, where differences in approval processes and regulatory capacity can affect the availability of quality-assured medical products.
Through coordinated scientific assessments and harmonised standards, the agency seeks to strengthen regulatory systems and support timely access to safe, effective and quality medical products.
The two PPB officials will serve initial two-year terms, during which they are expected to contribute their technical expertise to the agency's continental regulatory agenda.